Study S001562

A Phase 3, Open-Label, Multicenter, Single-Arm Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Dulaglutide 3.0 mg and 4.5 mg in Pediatric Participants 10 to Less Than 18 Years of Age With Type 2 Diabetes Mellitus

ClinicalTrials.gov record

Registration

Registration: NCT06739122
Study type: INTERVENTIONAL
Phase: PHASE3
Masking: NONE
Status: RECRUITING
Enrollment: 55
Start: 2025-01-10
Primary completion: 2027-12
Lead sponsor: Eli Lilly and Company
Conditions: Type 2 Diabetes
Interventions: DRUG:Dulaglutide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:H9X-MC-GBGS

Registered primary outcomes

Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration [Baseline through Week 26]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.